65LAB Launches In Partnership With Evotec SE
Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund, in collaboration with global life science company Evotec SE, have jointly launched 65LAB, a pioneering initiative aimed at advancing drug discovery and nurturing the creation of new therapeutic companies in Singapore. This marks the first collaboration of its kind in Singapore and was initiated by Lightstone Ventures with Evotec to leverage the global capabilities of its partners.
65LAB aims to accelerate the commercialization of promising research from top academic and R&D institutions in Singapore, including A*STAR, the National University of Singapore (NUS), and Duke-NUS Medical School. It seeks to combine Evotec's R&D platform with Singapore's academic and translational science and growing biotech infrastructure to create breakthrough therapies with global health impacts.
The collaboration selects promising academic projects and invests up to US$1.5 million in each project over 18-24 months. Scientists in partner institutions gain support from Evotec's Expert-in-Residence and access to the company's drug discovery, translational, and development capabilities. Upon project completion, investments and the creation of new companies are considered by 65LAB's board of global investors.
The core of 65LAB's collaboration is its Singapore-based academic and R&D partners, who aim to translate their research into commercial success and positive patient impact. This initiative seeks to foster long-term partnerships and contribute to the growth of Singapore's biotech ecosystem.
Overall, 65LAB represents a unique approach to driving scientific advancement and new therapeutic company formation by uniting global partners and Singapore's scientific talent.

Comments
Post a Comment